mouse interferon beta ifn β enzyme linked immunosorbent assay  (Elabscience Biotechnology)

Journal: Advanced Science

Article Title: RNA‐Binding Protein RBM25 Targets the mRNA Stability of GTPase Rab22a to Restrict Viral Entry and Infection

doi: 10.1002/advs.76160

Figure Lengend Snippet: RBM25 mediates antiviral protection independent of the IFN‐I signaling pathway. (A) A scheme of RNA‐seq analysis of WT and Rbm25 ‐cKO peritoneal macrophages infected with VSV for 4 h. (B) Heatmap of differentially expressed genes (DEGs) in Rbm25 ‐deficient and WT peritoneal macrophages infected with VSV for 4 h. (C) GSEA showing enrichment of DEGs in the pathways involving in the response to IFN‐α, IFN‐β production, JAK‐STAT3, IFN‐I receptor binding, toll like receptor, and cGAS target gene signaling pathways. (D) RT‐qPCR analysis of IFN‐I ( Ifna4, Ifnb1 ) mRNA in the lung tissues from WT and Rbm25 ‐cKO mice infected with PR8 influenza virus with a sublethal dose (50 PFU., n = 5 per group) at 7 dpi. (E) RT‐qPCR analysis of Cxcl10, Mx1, Isg15 , and Mx2 mRNA in the lung tissues from WT and Rbm25 ‐cKO mice treated as in (D). (F) ELISA of IFN‐β in serum from Rbm25 ‐cKO and WT mice infected with PR8 influenza virus, as in (D). (G) RT‐qPCR analysis of IFN‐I ( Ifna4, Ifnb1 ) mRNA in peritoneal macrophages from Rbm25 ‐cKO and WT mice infected with PR8 influenza virus for 12 h. (H) RT‐qPCR analysis of Cxcl10, Isg15 , and Rsad2 mRNA in peritoneal macrophages from WT and Rbm25 ‐cKO mice treated as in (G). (I) Immunoblots analysis of RBM25, RIG‐I, MAVS, p‐TBK1, TBK1, p‐IRF3, and IRF3 in peritoneal macrophages from WT and Rbm25 ‐cKO mice infected with PR8 influenza virus for the indicated times. β‐ACTIN was used as a loading control. (J) A scheme of experiment analyzing the infection of viruses in peritoneal macrophages from Irf3 −/− mice transfected with control siRNA or siRNA targeting Rbm25 . (K) RT‐qPCR analysis of PR8 HA and IAV M1, HSV‐1 TK and ICP0, VSV‐G mRNA in peritoneal macrophages from Irf3 −/− mice transfected with control siRNA or siRNA targeting Rbm25 followed by infection with PR8 influenza virus for 12 h, HSV‐1 for 12 h, or VSV for 8 h, respectively. (L, M) RT‐qPCR analysis of IFN‐I ( Ifna4, Ifnb1 ) mRNA in Rbm25 ‐cKO and WT peritoneal macrophages transfected with poly (I:C) for 4 h (L) or stimulated with UV‐VSV for 18 h (M). (N) Immunoblots analysis of p‐STAT1 and STAT1 in peritoneal macrophages from WT and Rbm25 ‐cKO mice infected with PR8 influenza virus for the indicated times. β‐ACTIN was used as a loading control. Data are presented as the mean ± SD. Unpaired two‐tailed Student's t ‐test (D–H, K–M). ns, not significant.

Article Snippet: IFN‐β levels in the supernatants or sera were measured using a mouse IFN‐β ELISA kit (PBL Biomedical Laboratories) according to the manufacturer's instructions.

Techniques: RNA Sequencing, Infection, Binding Assay, Protein-Protein interactions, Quantitative RT-PCR, Virus, Enzyme-linked Immunosorbent Assay, Western Blot, Control, Transfection, Two Tailed Test

Journal: Materials Today Bio

Article Title: Multiple-pathway cGAS-STING activation with enhanced mild photothermal therapy through glycolysis regulation for boosting gastric cancer immunotherapy

doi: 10.1016/j.mtbio.2026.102790

Figure Lengend Snippet: In vitro antitumor efficacy of the nanoparticles, ICD induction, and activation of the cGAS-STING pathway. Uptake of MOMn and MOMn@MB by MFC cells at (a) 4 and (b) 6 h. (c) Calcein-AM/PI and (d) JC-1 staining fluorescence images of MFC cells after treatment with different groups. Cytotoxicity analysis of MFC cells treated with (e) MO@MB and (f) MOMn@MB. Western blot analysis of (g) glycolysis pathway related proteins and (h) HSP70/90 in MFC cells treated with different nanoparticles. (i) CLSM images of CRT exposure on the surface of MFC cells after different treatments. (j) DNA damage assessment via γ-H2AX immunostaining in MFC cells treated with different nanoparticles. Levels of (k) lactate, (l) ATP, (m) HMGB1, and (n) IFN-β in MFC cells treated with different nanoparticles. (o) Western blot analysis of cGAS-STING pathway related proteins with different treatment. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. G1-G6 are denoted as Control, NIR Laser, MO@MB, MO@MB + NIR Laser, MOMn@MB, and MOMn@MB + NIR Laser groups, respectively.

Article Snippet: The mouse HMGB1 enzyme-linked immunosorbent assay (ELISA) kit and mouse interferon-β (IFN-β) ELISA kit were purchased from Wuhan Elabscience Biotechnology Co., Ltd.

Techniques: In Vitro, Activation Assay, Staining, Fluorescence, Western Blot, Immunostaining, Control

Journal: Materials Today Bio

Article Title: Multiple-pathway cGAS-STING activation with enhanced mild photothermal therapy through glycolysis regulation for boosting gastric cancer immunotherapy

doi: 10.1016/j.mtbio.2026.102790

Figure Lengend Snippet: DC maturation and activation of the cGAS-STING pathway. (a) Schematic diagram of the extraction from BMDCs to DC maturation and the Transwell assay. Created by Biorender. (b) Expression of CD80 and CD86 quantitatively determined by flow cytometry analysis with different treatments, and (c) the average DC maturation rate based on the results. (d) The levels of IFN-β in DC cells with different treatments. (e) Western blot analysis was employed to evaluate the expression of cGAS-STING pathway-related proteins in DC cells across different treatments. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. G1-G6 are denoted as Control, NIR Laser, MO@MB, MO@MB + NIR Laser, MOMn@MB, and MOMn@MB + NIR Laser groups, respectively.

Article Snippet: The mouse HMGB1 enzyme-linked immunosorbent assay (ELISA) kit and mouse interferon-β (IFN-β) ELISA kit were purchased from Wuhan Elabscience Biotechnology Co., Ltd.

Techniques: Activation Assay, Extraction, Transwell Assay, Expressing, Flow Cytometry, Western Blot, Control

Journal: Inflammation

Article Title: IRF7 Modulates Inflammatory Pain Through Upregulating IFNβ in Mice Trigeminal Ganglion

doi: 10.1007/s10753-026-02483-w

Figure Lengend Snippet: Expression of IRF7 and IFNβ in the TG during CFA-induced inflammatory pain. ( A ) Quantification of IFNβ levels in the TG and serum by ELISA before and after injection of CFA at 6 h, 1 d, 3 d post-CFA injection.( B ) Quantitative analysis of mRNA expression of Ifnb and Irf7 in the TG at 6 h, 1, 3 and 7 d post-CFA injection. ( C ) Time course of IRF7 and IFNβ expression in the TG during orofacial inflammatory pain and quantitative analysis of their expression levels normalized to GAPDH. ( D ) Quantitative analysis of mRNA expression of the key upstream factors (Sting1, Tlr4, Tlr3 and Irf3) related to IFNβ synthesis. Data are expressed as mean ± SD; N= 3-5 per group; one-way ANOVA followed by post hoc test was performed to assess significance between groups (*P < 0.05, **P < 0.01)

Article Snippet: IFNβ levels in serum and TG were quantified using ELISA kits (E-EL-M0033, Elabscience Biotechnology), according to the manufacturer’s instructions.

Techniques: Expressing, Enzyme-linked Immunosorbent Assay, Injection